Cited by 1,575Cancer Immunotherapy and BiomarkersImmunotherapy and Immune ResponsesT-cell and B-cell Immunology

The DOI matches its Crossref record; 37 of the 38 references it cites were found in a registry or an index.

Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma

Open access

Phan, Giao Q., Yang, James C., Sherry, Richard M., Hwu, Patrick, Topalian, Suzanne L., Schwartzentruber, Douglas J., Restifo, Nicholas P., Haworth, Leah R., Seipp, Claudia A., Freezer, Linda J., Morton, Kathleen E., Mavroukakis, Sharon A., Duray, Paul H., Steinberg, Seth M., Allison, James P., Davis, Thomas A., Rosenberg, Steven A.·2003·Proceedings of the National Academy of Sciences

DOI 10.1073/pnas.1533209100PMC PMC166236

Open this paper in CoChat — free account

Abstract

Cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) is a critical immunoregulatory molecule (expressed on activated T cells and a subset of regulatory T cells) capable of down-regulating T cell activation. Blockade of CTLA-4 has been shown in animal models to improve the effectiveness of cancer immunotherapy. We thus treated 14 patients with metastatic melanoma by using serial i.v. administration of a fully human anti-CTLA-4 antibody (MDX-010) in conjunction with s.c. vaccination with two modified HLA-A*0201-restricted peptides from the gp100 melanoma-associated antigen, gp100:209-217(210M) and gp100:280-288(288V). This blockade of CTLA-4 induced grade III/IV autoimmune manifestations in six patients (43%), including dermatitis, enterocolitis, hepatitis, and hypophysitis, and mediated objective cancer regression in three patients (21%; two complete and one partial responses). This study establishes CTLA-4 as an important molecule regulating tolerance to "self" antigens in humans and suggests a role for CTLA-4 blockade in breaking tolerance to human cancer antigens for cancer immunotherapy.

Integrity signals

Registry

Crossref · 10.1073/pnas.1533209100

Cites

37 of 37 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Enhancement of Antitumor Immunity by CTLA-4 Blockade
Leach, D. R., Krummel, M. F., & Allison, J. P. (1996) · Science · doi:10.1126/science.271.5256.1734 · Cited by 3,955
Self-citation
Lymphoproliferative Disorders with Early Lethality in Mice Deficient in Ctla-4
Waterhouse, P., Penninger, J. M., Timms, E., Wakeham, A., Shahinian, A., Lee, K. P., Thompson, C. B., Griesser, H., & Mak, T. W. (1995) · Science · doi:10.1126/science.270.5238.985 · Cited by 2,766
CD4+CD25+ Immunoregulatory T Cells Suppress Polyclonal T Cell Activation In Vitro by Inhibiting Interleukin 2 Production
Thornton, A. M., & Shevach, E. M. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.188.2.287 · Cited by 2,637
CTLA-4 can function as a negative regulator of T cell activation
Walunas, T. L., Lenschow, D. J., Bakker, C. Y., Linsley, P. S., Freeman, G. J., Green, J. M., Thompson, C. B., & Bluestone, J. A. (1994) · Immunity · doi:10.1016/1074-7613(94)90071-x · Cited by 2,222
Cytotoxic T Lymphocyte–Associated Antigen 4 Plays an Essential Role in the Function of Cd25+Cd4+ Regulatory Cells That Control Intestinal Inflammation
Read, S., Malmström, V., & Powrie, F. M. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.2.295 · Cited by 2,206
A cell culture model for T lymphocyte clonal anergy
Schwartz, R. H. (1990) · Science · doi:10.1126/science.2113314 · Cited by 1,857
Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma
Rosenberg, S. A., Yang, J. C., Schwartzentruber, D. J., Hwu, P., Marincola, F. M., Topalian, S. L., Restifo, N. P., Dudley, M. E., Schwarz, S. L., Spiess, P. J., et al. (1998) · Nature Medicine · doi:10.1038/nm0398-321 · Cited by 1,786
Self-citation
A Theory of Self-Nonself Discrimination
Bretscher, P., & Cohn, M. (1970) · Science · doi:10.1126/science.169.3950.1042 · Cited by 1,755
CTLA-4 is a second receptor for the B cell activation antigen B7.
Linsley, P. S., Brady, W., Urnes, M., Grosmaire, L. S., Damle, N. K., & Ledbetter, J. A. (1991) · The Journal of experimental medicine · doi:10.1084/jem.174.3.561 · Cited by 1,685
A new member of the immunoglobulin superfamily—CTLA-4
Brunet, J., Denizot, F., Luciani, M., Roux-Rouquié, M., Suzan, M., Mattéi, M., & Golstein, P. (1987) · Nature · doi:10.1038/328267a0 · Cited by 1,307

Show all 38 references

Research works printed but not linked: 4

Alegre, M. L., Frauwirth, K. A. & Thompson, C. B. (2002) Nat. Rev. Immunol. 1, 220-228.
Hurwitz, A. A., Foster, B. A., Kwon, E. D., Truong, T., Choi, E. M., Greenberg, N. M., Burg, M. B. & Allison, J. P. (2000) Cancer Res. 60, 2444-2448.10811122
Pass, H. A., Schwarz, S. L., Wunderlich, J. R. & Rosenberg, S. A. (1998) Cancer J. Sci. Am. 4, 316-323.9815296
Angelini, G., Gardella, S., Ardy, M., Ciriolo, M. R., Filomeni, G., Di Trapani, G., Clarke, F., Sitia, R. & Rubartelli, A. (2002) Proc. Natl. Acad. Sci. USA 99, 1471-1476.

Sorted by citations

Items 901–1,000 of 1,000

The synergistic strategies for the immuno‐oncotherapy with photothermal nanoagents
Zhang, Y., Zhang, G., Wang, G., Wu, L., Monteiro-Riviere, N. A., & Li, Y. (2021) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1717 · Cited by 20
Oncophage: step to the future for vaccine therapy in melanoma
di Pietro, A., Tosti, G., Ferrucci, P. F., & Testori, A. (2008) · Expert Opinion on Biological Therapy · doi:10.1517/14712590802517970 · Cited by 21
Exploiting Regulatory T-cell Populations for the Immunotherapy of Cancer
van der Vliet, H. J., Koon, H. B., Atkins, M. B., Balk, S. P., & Exley, M. A. (2007) · Journal of Immunotherapy · doi:10.1097/cji.0b013e31805ca058 · Cited by 20
Anticalins®: the lipocalin family as a novel protein scaffold for the development of next-generation immunotherapies
Hohlbaum, A. M., & Skerra, A. (2007) · Expert Review of Clinical Immunology · doi:10.1586/1744666x.3.4.491 · Cited by 20
Molecular regulation of Th2 immunity by dendritic cells
Grünig, G., Banz, A., & Malefyt, R. D. W. (2004) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2004.11.004 · Cited by 20
Systemic Therapy for Cutaneous Melanoma
Treisman, J. S., & Garlie, N. K. (2009) · Clinics in Plastic Surgery · doi:10.1016/j.cps.2009.07.008 · Cited by 20
Augmenting the Potency of Breast Cancer Vaccines: Combined Modality Immunotherapy
Emens, L. A., Reilly, R. T., & Jaffee, E. M. (2004) · Breast Disease · doi:10.3233/bd-2004-20103 · Cited by 20
An Update on Malignant Melanoma Vaccine Research
Ralph, S. J. (2007) · American Journal of Clinical Dermatology · doi:10.2165/00128071-200708030-00001 · Cited by 20
DNA Vaccines Against Cancer
Stan, R., Wolchok, J. D., & Cohen, A. D. (2006) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2006.02.004 · Cited by 20
Altering immune tolerance therapeutically: the power of negative thinking
Prud’homme, G. J. (2003) · Journal of Leukocyte Biology · doi:10.1189/jlb.0803394 · Cited by 20
Melanoma Vaccines
Chapman, P. B. (2007) · Seminars in Oncology · doi:10.1053/j.seminoncol.2007.09.013 · Cited by 20
Modulation of antitumor responses by dendritic cells
Vieweg, J., & Jackson, A. M. (2004) · Springer Seminars in Immunopathology · doi:10.1007/s00281-004-0175-1 · Cited by 20
Vaccines and Immunostimulants
Schlom, J., Gulley, J. L., & Hodge, J. W. (2017) · Wiley eBooks · doi:10.1002/9781119000822.hfcm066 · Cited by 20
Immunotherapy for solid tumors—a review for surgeons
Calvino, A. S., Pillarisetty, V. G., & Katz, S. C. (2013) · Journal of Surgical Research · doi:10.1016/j.jss.2013.12.018 · Cited by 19
Immunotherapy for lung cancer: for whom the bell tolls?
Madureira, P., de Mello, R. A., de Vasconcelos, A., & Zhang, Y. (2015) · Tumor Biology · doi:10.1007/s13277-015-3285-6 · Cited by 19
Nanomedicine for Immunotherapy Targeting Hematological Malignancies: Current Approaches and Perspective
Allegra, A., Gioacchino, M. D., Tonacci, A., Petrarca, C., & Gangemi, S. (2021) · Nanomaterials · doi:10.3390/nano11112792 · Cited by 19
Large-scale assembly and pattern transfer of SERS-active nanoparticles for application in drug monitoring of methotrexate in blood serum
Panikar, S. S., Cialla‐May, D., Haaß, T., Hübner, U., González, A. L., Salas, P., & Popp, J. (2022) · Vibrational Spectroscopy · doi:10.1016/j.vibspec.2022.103470 · Cited by 19
Fragmented antibodies in non-small cell lung cancer: A novel nano-engineered delivery system for detection and treatment of cancer
Nijhawan, H. P., Prabhakar, B. R., Misra, A. R., & Yadav, K. S. (2023) · Drug Discovery Today · doi:10.1016/j.drudis.2023.103701 · Cited by 19
Ipilimumab for advanced melanoma: A pharmacologic perspective
Trinh, V. A., & Hagen, B. (2012) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155212459100 · Cited by 19
MUC1 Story: Great Expectations, Disappointments and the Renaissance
Syrkina, M. S., Vassetzky, Y. S., & Rubtsov, M. A. (2019) · Current Medicinal Chemistry · doi:10.2174/0929867324666170817151954 · Cited by 19
Pair Correlation Analysis Maps the Dynamic Two-Dimensional Organization of Natural Killer Cell Receptors at the Synapse
Hedde, P. N., Staaf, E., Singh, S. B., Johansson, S., & Gratton, E. (2019) · ACS Nano · doi:10.1021/acsnano.9b07486 · Cited by 19
Treatment of Melanoma and Nonmelanoma Skin Cancer
Rass, K., & Tilgen, W. (2009) · Advances in experimental medicine and biology · doi:10.1007/978-0-387-77574-6_23 · Cited by 19
Targeting metastatic melanoma
Poust, J. (2008) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp080461 · Cited by 19
GMP production of anti-tumor cytotoxic T-cell lines for adoptive T-cell therapy in patients with solid neoplasia
Turin, I., Pedrazzoli, P., Tullio, C., Montini, E., Grotteria, M. C. L., Schiavo, R., Perotti, C. G., Locatelli, F., Carretto, E., Maccario, R., et al. (2007) · Cytotherapy · doi:10.1080/14653240701405428 · Cited by 19
Modulation of Immune Response by B7 Family Molecules in Tumor Microenvironments
Flies, D. B., & Chen, L. (2006) · Immunological Investigations · doi:10.1080/08820130600755017 · Cited by 20
Exploiting Dendritic Cells for Active Immunotherapy of Cancer and Chronic Infection
O’Neill, D. W., & Bhardwaj, N. (2004) · Humana Press eBooks · doi:10.1385/1-59259-862-5:001 · Cited by 19
Development of Immunotherapy for Pancreatic Cancer
Kawakami, Y., Okada, T., & Akada, M. (2004) · Pancreas · doi:10.1097/00006676-200404000-00021 · Cited by 19
Cutaneous Events Associated with Immunotherapy of Melanoma: A Review
Burzi, L., Alessandrini, A. M., Quaglino, P., Piraccini, B. M., Dika, E., & Ribero, S. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10143047 · Cited by 18
Cytotoxic T-Lymphocyte Antigen-4 Genetic Variants and Risk of Ewing's Sarcoma
Feng, D., Yang, X., Li, S., Liu, T., Wu, Z., Song, Y., Wang, J., Gao, W., Huang, Q., Huang, W., et al. (2013) · Genetic Testing and Molecular Biomarkers · doi:10.1089/gtmb.2012.0488 · Cited by 18
From clinical trials to clinical practice: therapeutic cancer vaccines for the treatment of prostate cancer
Madan, R. A., Aragon‐Ching, J. B., Gulley, J. L., & Dahut, W. L. (2011) · Expert Review of Vaccines · doi:10.1586/erv.11.70 · Cited by 18
PD-L1, TIM-3, and CTLA-4 Blockade Fails To Promote Resistance to Secondary Infection with Virulent Strains of Toxoplasma gondii
Splitt, S. D., Souza, S. P., Valentine, K. M., Castellanos, B. E., Curd, A. B., Hoyer, K. K., & Jensen, K. D. C. (2018) · Infection and Immunity · doi:10.1128/iai.00459-18 · Cited by 19
Identification of Tumor Antigens in the HLA Peptidome of Patient-derived Xenograft Tumors in Mouse
Rijensky, N. M., Blondheim-Shraga, N., Barnea, E., Peled, N., Rosenbaum, E., Popovtzer, A., Stemmer, S. M., Livoff, A., Shlapobersky, M., Moskovits, N. B.-C., et al. (2020) · Molecular & Cellular Proteomics · doi:10.1074/mcp.ra119.001876 · Cited by 18
Cytotoxic T lymphocyte‐associated protein 4 antibody aggrandizes antitumor immune response of oncolytic virus M1 via targeting regulatory T cells
Liu, W., Liu, Y., Hu, C., Xu, C., Chen, J., Chen, Y., Cai, J., Yan, G., & Zhu, W. (2021) · International Journal of Cancer · doi:10.1002/ijc.33703 · Cited by 18
Advances of DNA Damage Repair-Related Drugs and Combination With Immunotherapy in Tumor Treatment
Wang, Y., Duan, M.-H., Peng, Z., Fan, R., He, Y., Zhang, H., Xiong, W., & Jiang, W. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.854730 · Cited by 18
Immune checkpoint blockade in melanoma: Advantages, shortcomings and emerging roles of the nanoparticles
Gorabi, A. M., Ravari, M. S., Sanaei, M., Davaran, S., Kesharwani, P., & Sahebkar, A. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.109300 · Cited by 18
Manipulating TGF-β signaling to optimize immunotherapy for cervical cancer
Yin, S., Cui, H., Qin, S., & Yu, S. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115355 · Cited by 18
The Dermis as a Portal for Dendritic Cell-Targeted Immunotherapy of Cutaneous Melanoma
Oosterhoff, D., Sluijter, B. J. R., Hangalapura, B. N., & de Gruijl, T. D. (2011) · Current topics in microbiology and immunology · doi:10.1007/82_2011_136 · Cited by 18
Dendritic cell immunotherapy for breast cancer
Pinzón‐Charry, A., Schmidt, C., & López, J. A. (2006) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.6.6.591 · Cited by 18
Regulating Suppression
Shevach, E. M. (2008) · Science · doi:10.1126/science.1164872 · Cited by 18
Pituitary Dysfunction: A Case Series of Immune Checkpoint Inhibitor–Related Hypophysitis in an Emergency Department
Miller, A. H., Brock, P. A., & Yeung, S. J. (2016) · Annals of Emergency Medicine · doi:10.1016/j.annemergmed.2016.03.048 · Cited by 18
Diagnosis and management of chronic and refractory immune cytopenias in children, adolescents, and young adults
Rotz, S. J., Ware, R. E., & Kumar, A. R. (2018) · Pediatric Blood & Cancer · doi:10.1002/pbc.27260 · Cited by 18
Therapeutic potential of immunostimulatory monoclonal antibodies
Gray, J. C., Johnson, P., & Glennie, M. J. (2006) · Clinical Science · doi:10.1042/cs20060024 · Cited by 18
CTLA‐4 regulates the murine immune response to Trypanosoma cruzi infection
Graefe, S. E. B., Jacobs, T., Wächter, U., Bröker, B. M., & Fleischer, B. (2004) · Parasite Immunology · doi:10.1111/j.0141-9838.2004.00679.x · Cited by 18
Therapeutic lymphoma vaccines: importance of T-cell immunity
Neelapu, S. S., Lee, S., Qin, H., Cha, S.-C., Woo, A. F., & Kwak, L. W. (2006) · Expert Review of Vaccines · doi:10.1586/14760584.5.3.381 · Cited by 18
The clinical utility of cytotoxic T lymphocyte antigen 4 abrogation by human antibodies
Weber, J. S. (2006) · Melanoma Research · doi:10.1097/01.cmr.0000232292.06785.a3 · Cited by 18
Immunotherapy for lung cancer
Sathish, G., Monavarshini, L. K., Sundaram, K., Sendilvelan, S., & Gomathi, K. (2024) · Pathology - Research and Practice · doi:10.1016/j.prp.2024.155104 · Cited by 18
Folate-conjugated immunoglobulin targets melanoma tumor cells for NK cell effector functions
Skinner, C. C., McMichael, E. L., Jaime‐Ramirez, A. C., Abrams, Z. B., Lee, R. J., & Carson, W. E. (2016) · Melanoma Research · doi:10.1097/cmr.0000000000000258 · Cited by 17
Breaking Tolerance—Another Piece Added to the Vitiligo Puzzle
Lee, D. J., & Modlin, R. L. (2005) · Journal of Investigative Dermatology · doi:10.1111/j.0022-202x.2004.23553.x · Cited by 17
HSPPC-96 vaccine in metastatic melanoma patients: from the state of the art to a possible future
Tosti, G., di Pietro, A., Ferrucci, P. F., & Testori, A. (2009) · Expert Review of Vaccines · doi:10.1586/erv.09.108 · Cited by 17
Immunotherapy for gastrointestinal cancer: current status and strategies for improving efficacy
Elkord, E., Hawkins, R. E., & Stern, P. L. (2008) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.8.4.385 · Cited by 17
Antisense therapy for restenosis following percutaneous coronary intervention
Kipshidze, N. N., Tsapenko, M. V., Iversen, P. L., & Burger, D. R. (2005) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.5.1.79 · Cited by 17
Effect of cytotoxic T-lymphocyte antigen-4, TNF-alpha polymorphisms on osteosarcoma: evidences from a meta-analysis.
(2013) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.1000-9604.2013.11.06 · Cited by 16
Melanoma antigens recognized by T cells and their use for immunotherapy
Ohta, S., Misawa, A., Kyi‐Tha‐Thu, C., Matsumoto, N., Hirose, Y., & Kawakami, Y. (2023) · Experimental Dermatology · doi:10.1111/exd.14741 · Cited by 17
Progress and Challenges of Immune Checkpoint Inhibitor-Induced Hypophysitis
Chen, P. L., Li, J., & Tan, H. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12103468 · Cited by 16
Operative Management of Metastatic Melanoma in Bone May Require En Bloc Resection of Disease
Krygier, J. E., Lewis, V. O., Cannon, C. P., Satcher, R. L., Moon, B. S., & Lin, P. P. (2014) · Clinical Orthopaedics and Related Research · doi:10.1007/s11999-014-3761-0 · Cited by 16
Current Trends in Glioblastoma Multiforme Treatment: Radiation Therapy and Immune Checkpoint Inhibitors
Nicholas, S. E., Mathios, D., Ruzevick, J., Jackson, C. M., Yang, I., & Lim, M. K. (2013) · Brain Tumor Research and Treatment · doi:10.14791/btrt.2013.1.1.2 · Cited by 16
The Availability of a Functional Tumor Targeting T-Cell Repertoire Determines the Anti-Tumor Efficiency of Combination Therapy with Anti-CTLA-4 and Anti-4-1BB Antibodies
Jensen, B. A. H., Pedersen, S. R., Christensen, J. P., & Thomsen, A. R. (2013) · PLoS ONE · doi:10.1371/journal.pone.0066081 · Cited by 16
E xploring G lucocorticoid R eceptor A gonists M echanism of A ction T hrough M ass C ytometry and R adial V isualizations
Abraham, Y., Gerrits, B., Ludwig, M., Rebhan, M., & Keller, C. G. (2016) · Cytometry Part B Clinical Cytometry · doi:10.1002/cyto.b.21499 · Cited by 16
Large-scale database mining reveals hidden trends and future directions for cancer immunotherapy
Kather, J. N., Berghoff, A. S., Ferber, D., Suarez‐Carmona, M., Reyes‐Aldasoro, C. C., Valous, N. A., Moraleda, R. R., Jäger, D., & Halama, N. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1444412 · Cited by 16
Immune-checkpoint inhibitors to treat cancers in specific immunocompromised populations: a critical review
Babey, H., Quéré, G., Descourt, R., Calloch, R. L., Lanfranco, L., Nousbaum, J., Cornec, D., Tison, A., & CHOUAID, C. (2018) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2018.1499468 · Cited by 18
Prospects of biological and synthetic pharmacotherapies for glioblastoma
Altshuler, D. B., Kadiyala, P., Núñez, F. J., Núñez, F. M., Carney, S. V., Alghamri, M. S., Garcia-Fabiani, M. B., Asad, A. S., Candia, A. J. N., Candolfi, M., et al. (2020) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2020.1713085 · Cited by 16
Phytochemical Targeting of STAT3 Orchestrated Lipid Metabolism in Therapy-Resistant Cancers
Tse, C., Warner, A., Farook, R., & Cronin, J. (2020) · Biomolecules · doi:10.3390/biom10081118 · Cited by 16
Immunotherapy and therapeutic vaccines in prostate cancer: an update on current strategies and clinical implications
Gulley, J. L., & Singh, B. H. (2014) · Asian Journal of Andrology · doi:10.4103/1008-682x.122585 · Cited by 16
Thoracic metastasectomy for adoptive immunotherapy of melanoma: A single-institution experience
Klapper, J. A., Davis, J. L., Ripley, R. T., Smith, F. O., Nguyen, D. M., Kwong, K. F., Mercedes, L., Kemp, C. D., Mathur, A., White, D. E., et al. (2010) · Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2010.05.020 · Cited by 16
Self-citation
Immunotherapy of Melanoma
Rietschel, P., & Chapman, P. B. (2006) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2006.02.005 · Cited by 16
Novel Therapies for Metastatic Melanoma: An Update on Their Use in Older Patients
Rogiers, A., van den Oord, J. J., Garmyn, M., Stas, M., Kenis, C., Wildiers, H. P. M. W., Marine, J., & Wolter, P. (2015) · Drugs & Aging · doi:10.1007/s40266-015-0304-7 · Cited by 16
Immunotherapy of advanced or metastatic melanoma.
Cebon, J. S., Gedye, C. A., John, T., & Davis, I. D. (2007) · PubMed · Cited by 16
Endocrine adverse events related to immune-oncology agents: retrospective experience of a single institution
España, S., de, A. P.-M., Marqués-Pamies, M., Cucurull, M., Doménech, M., Velarde, J. M., Salinas, I., Morán, T., & Etxániz, O. (2020) · Translational Lung Cancer Research · doi:10.21037/tlcr.2019.12.17 · Cited by 16
A quest for therapeutic antigens in bone and soft tissue sarcoma
Kawaguchi, S., Wada, T., Tsukahara, T., Ida, K., Torigoe, T., Sato, N., & Yamashita, T. (2005) · Journal of Translational Medicine · doi:10.1186/1479-5876-3-31 · Cited by 16
Immunologic mechanisms in RCC and allogeneic renal transplant rejection
Bedke, J., & Stenzl, A. (2010) · Nature Reviews Urology · doi:10.1038/nrurol.2010.59 · Cited by 16
Emerging biological therapies in rheumatoid arthritis
Xavier Mariette, A. (2004) · Joint Bone Spine · doi:10.1016/j.jbspin.2004.07.008 · Cited by 16
Novel agents in development for the treatment of melanoma
Tarhini, A. A., & Agarwala, S. S. (2005) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.14.7.885 · Cited by 16
New battlefields for costimulation
Martín‐Orozco, N., & Dong, C. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20060219 · Cited by 16
Current State and Perspectives of Dendritic Cell Vaccination in Cancer Immunotherapy
Farkas, Á., Conrad, C., Tonel, G., Borbényi, Z., Kemény, L. V., DOBOZY, A., & Nestle, F. O. (2006) · Skin Pharmacology and Physiology · doi:10.1159/000092592 · Cited by 16
Central Nervous System Tumor Immunity Generated by a Recombinant Listeria monocytogenes Vaccine Targeting Tyrosinase Related Protein-2 and Real-Time Imaging of Intracranial Tumor Burden
Prins, R. M., Bruhn, K. W., Craft, N. A., Lin, J. W., Kim, C. H., Odesa, S. K., Miller, J. F., & Liau, L. M. (2005) · Neurosurgery · doi:10.1227/01.neu.0000192367.29047.64 · Cited by 16
Active Antigen‐specific Immunotherapy of Melanoma: from Basic Science to Clinical Investigation
Spagnoli, G. C., Adamina, M., Bolli, M., Weber, W. P., Zajac, P., Marti, W., Oertli, D., Heberer, M., & Harder, F. H. (2005) · World Journal of Surgery · doi:10.1007/s00268-005-7762-8 · Cited by 16
Immune Infiltration and Clinical Outcome of Super-Enhancer-Associated lncRNAs in Stomach Adenocarcinoma
Peng, L., Peng, J., Cai, D., Qiu, Y., Lan, Q., Luo, J., Yang, B., Xie, H.-T., Du, Z., Yuan, X., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.780493 · Cited by 15
Dividing and conquering: controlling advanced melanoma by targeting oncogene-defined subsets
Flaherty, K. T. (2012) · Clinical & Experimental Metastasis · doi:10.1007/s10585-012-9488-y · Cited by 15
Multicenter phase II study of chemoimmunotherapy in the treatment of metastatic melanoma
Recchia, F., Candeloro, G., Necozione, S., Fumagalli, L. A. M., Bratta, M., & Rea, S. (2008) · Anti-Cancer Drugs · doi:10.1097/cad.0b013e3282f2c0bc · Cited by 15
Melanoma Immunotherapy
Sivendran, S., Glodny, B., Pan, M. M., Mérad, M., & Saenger, Y. M. (2010) · Mount Sinai Journal of Medicine A Journal of Translational and Personalized Medicine · doi:10.1002/msj.20215 · Cited by 15
Pembrolizumab-induced myasthenia gravis-like disorder, ocular myositis, and hepatitis: a case report
Tian, C.-Y., Ou, Y.-H., Chang, S., & Lin, C. (2021) · Journal of Medical Case Reports · doi:10.1186/s13256-021-02722-8 · Cited by 17
Structural Characterization of a Macrocyclic Peptide Modulator of the PD-1/PD-L1 Immune Checkpoint Axis
Żyła, E., Musielak, B., Holak, T. A., & Dubin, G. (2021) · Molecules · doi:10.3390/molecules26164848 · Cited by 15
Epitranscriptomic Approach: To Improve the Efficacy of ICB Therapy by Co-Targeting Intracellular Checkpoint CISH
Kumar, S., Sarthi, P., Mani, I., Ashraf, M. U., Kang, M.-H., Kumar, V., & Bae, Y. (2021) · Cells · doi:10.3390/cells10092250 · Cited by 16
Monoclonal Antibodies to CTLA-4 with Focus on Ipilimumab
Graziani, G., Lisi, L., Tentori, L., & Navarra, P. (2022) · Experientia supplementum · doi:10.1007/978-3-030-91311-3_10 · Cited by 16
Immune-Checkpoints : les nouvelles immunothérapies anticancéreuses
Ileana, E. E., Champiat, S., & Soria, J. (2013) · Bulletin du Cancer · doi:10.1684/bdc.2013.1771 · Cited by 16
Preclinical Safety Evaluation of Monoclonal Antibodies
Lynch, C. M., & Grewal, I. S. (2007) · Handbook of experimental pharmacology · doi:10.1007/978-3-540-73259-4_2 · Cited by 17
Modulating T-cell-based cancer immunotherapy via particulate systems
Truong, D. H., Tran, T. T. P., Nguyen, H. T., Phung, C. D., Pham, T. T., Yong, C. S., Kim, J. O., & Tran, T. H. (2018) · Journal of drug targeting · doi:10.1080/1061186x.2018.1474360 · Cited by 15
Immunotherapy of malignant melanoma – Basic principles and novel therapeutic approaches
Enk, A., Becker, J. C., & Schuler, G. (2006) · JDDG Journal der Deutschen Dermatologischen Gesellschaft · doi:10.1111/j.1610-0387.2005.05038.x-i1 · Cited by 15
Oncophage®(vitespen®) - Heat shock protein peptide complex 96-based vaccines in melanoma: How far we are, how far we can get?
di Pietro, A., Tosti, G., Ferrucci, P. F., & Testori, A. (2009) · Human Vaccines · doi:10.4161/hv.5.11.9881 · Cited by 15
General Principles of Tumor Immunotherapy
Kaufman, H. L., & Wolchok, J. D. (2007) · Springer eBooks · doi:10.1007/978-1-4020-6087-8 · Cited by 15
T cell-mediated immunotherapy of metastases: state of the art in 2005
Schirrmacher, V. (2005) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.5.8.1051 · Cited by 15
Danger signals in tumor cells: a risk factor for autoimmune disease?
Schirrmacher, V., & Fournier, P. (2010) · Expert Review of Vaccines · doi:10.1586/erv.10.15 · Cited by 14
T-Cell Costimulation and Its Applications in Diseases
Mir, M. A. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-802585-7.00006-6 · Cited by 15
Association of genetic polymorphisms with osteosarcoma risk: a meta-analysis.
Bian, Z., He, Q., Wang, X., Li, M., & Zhu, L. (2015) · Europe PMC (PubMed Central) · Cited by 14
Concept of Reverse Costimulation and Its Role in Diseases
Mir, M. A. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-802585-7.00002-9 · Cited by 14
Low immunogenicity in non-small cell lung cancer; do new developments and novel treatments have a role?
Gardiner, R., Jahangeer, S. M., Forde, P. F., Ariffin, A. B., Bird, B., Soden, D. M., & Hinchion, J. (2015) · Cancer and Metastasis Reviews · doi:10.1007/s10555-015-9550-8 · Cited by 14
Preclinical vaccines against mammary carcinoma
Lollini, P., Cavallo, F., Giovanni, C. D., & Nanni, P. (2013) · Expert Review of Vaccines · doi:10.1586/14760584.2013.845530 · Cited by 14
Synthetic Cystine-Knot Miniproteins – Valuable Scaffolds for Polypeptide Engineering
Avrutina, O. (2016) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-32805-8_7 · Cited by 14
Function and dysfunction of dendritic cells in autoimmune rheumatic diseases
Rutella, S., CRISTOFARO, R. D., & Ferraccioli, G. (2009) · Human Immunology · doi:10.1016/j.humimm.2009.01.023 · Cited by 14
From Breast Cancer Immunobiology to Her-2 DNA Vaccine and Autoimmune Sequelae
Miller, F. W., Jones, R. F., Jacob, J. B., Kong, Y.-C. M., & Wei, W. (2004) · Breast Disease · doi:10.3233/bd-2004-20106 · Cited by 14

Authors: Phan, G. Q., Yang, J. C., Sherry, R. M., Hwu, P., Topalian, S. L., Schwartzentruber, D. J., Restifo, N. P., Haworth, L. R., Seipp, C. A., Freezer, L. J., Morton, K. E., Mavroukakis, S. A., Duray, P. H., Steinberg, S. M., Allison, J. P., Davis, T. A., & Rosenberg, S. A.
Affiliations: National Institutes of Health (US)
Surgery Branch, Laboratory of Pathology, and Biostatistics and Data Management Section, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892; Howard Hughes Medical Institute, Department of Molecular and Cell Biology, University of California, Berkeley, CA 94720; and Medarex, Inc., Princeton, NJ 08540
ORCID: Phan, Giao Q.
Yang, James C.
Sherry, Richard M.
Hwu, Patrick
Topalian, Suzanne L.
Restifo, Nicholas P.
Mavroukakis, Sharon A.
Steinberg, Seth M.
Allison, James P.
Davis, Thomas A.
Rosenberg, Steven A.
Venue: Proceedings of the National Academy of Sciences
Publisher: National Academy of Sciences
Published: 2003-06-25
Volume: 100
Issue: 14
Pages: 8372-8377
ISSN: 0027-8424 (ISSN-L)
1091-6490
DOI: 10.1073/pnas.1533209100
PMC: PMC166236
OpenAlex: W2134638467
Cited by: 1,575
References: 38
Citations by year: 2026: 10 · 2025: 11 · 2024: 26 · 2023: 41 · 2022: 48 · 2021: 52 · 2020: 58 · 2019: 56 · 2018: 68 · 2017: 82 · 2016: 58 · 2015: 72 · 2014: 70 · 2013: 78 · 2012: 72
FWCI: 46.70
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Locations: Proceedings of the National Academy of Sciences (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
Funders: National Institutes of Health (Z99 CA999999)
National Cancer Institute (Z01BC010763)
Topics: Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
Keywords: CTLA-4 blockade, metastatic melanoma, autoimmunity, tumor regression, anti-CTLA-4 antibody, HLA-A*0201, cancer immunotherapy, self-tolerance, regulatory T cells, T cell activation, enterocolitis, hypophysitis, hepatitis, skin inflammation
MeSH terms: Adult, Antibodies, Monoclonal, Antibodies, Neoplasm, Antigens, Differentiation, Antigens, Neoplasm, Autoimmune Diseases, Colitis, Dermatitis, Female, Humans, Immune Tolerance, Immunotherapy, Injections, Intravenous, Injections, Subcutaneous, Lymphocyte Activation, Male, Melanoma, Membrane Glycoproteins, Middle Aged, Neoplasm Metastasis, Neoplasm Proteins, Peptide Fragments, Peptides, T-Lymphocytes, Cytotoxic, Vaccination, Vitiligo, Antigens, CD, HLA-A2 Antigen, T-Lymphocyte Subsets, Salvage Therapy, Hepatitis, Autoimmune, gp100 Melanoma Antigen, CTLA-4 Antigen

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks